FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to a bispecific antigen-binding molecule binding to OX40 and FAP, which contains at least one Fab-fragment having the capability of specific binding to OX40, and at least one fragment having the capability of specific binding to a fibroblast-activating protein (FAP), as well as to a composition containing it. Polynucleotide encoding the above-mentioned molecule is also disclosed.
EFFECT: invention is effective for stimulating T-cell response.
11 cl, 44 dwg, 73 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
| MOLECULES BINDING TO 4-1BB | 2011 |
|
RU2551963C2 |
| T-CELL RECEPTORS RECOGNIZING R175H OR Y220C MUTATION IN p53 | 2020 |
|
RU2830061C2 |
| BISPECIFIC 2+1 ANTIBODIES | 2018 |
|
RU2797305C2 |
| EMBODIMENTS OF SIRP-ALPHA-4-1BBL FUSION PROTEIN AND METHODS OF USE THEREOF | 2019 |
|
RU2815515C2 |
| TRUNCATED CHIMERIC RECEPTORS NKG2D AND THEIR WAYS OF USE IN IMMUNOTHERAPY USING NATURAL KILLER CELLS | 2018 |
|
RU2830556C2 |
| T- CELLS WITH COSTIMULATING CHIMERIC ANTIGEN RECEPTOR TARGETING IL13Rα2 | 2015 |
|
RU2749922C2 |
| BCMA-TARGETED ANTIBODY AND ITS USE | 2018 |
|
RU2799655C2 |
| INTRODUCTION OF CONSTRUCTED T CELLS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CANCER | 2017 |
|
RU2757308C2 |
| ANTI-CLL1-SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGENIC RECEPTORS (SCCAR) FOR CANCER IMMUNOTHERAPY | 2016 |
|
RU2731543C2 |
